Tetrabenazine: Spotlight on drug review

Annals of Neurosciences

Volumn 23, Issue 3, 2016, Pages 176-185

  Kaur, Navneet ^a   Kumar, Puneet ^a   Jamwal, Sumit ^a   Deshmukh, Rahul ^a   Gauttam, Vinod ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Basal ganglia; Chorea; Huntington s chorea; Treatment

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; QUINIDINE; RESERPINE; TETRABENAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

AGITATION; AKATHISIA; ANXIETY; BALANCE DISORDER; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; ENZYME INHIBITION; EXOCYTOSIS; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HEMIBALLISM; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; INSOMNIA; KIDNEY FAILURE; LIVER FAILURE; MENTAL DISEASE; MOLECULAR WEIGHT; MOTOR DYSFUNCTION; MYOCLONUS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PANIC; PARKINSONISM; PREGNANCY; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TIC;

EID: 84999645048     PISSN: 09727531     EISSN: 09763260     Source Type: Journal    
DOI: 10.1159/000449184     Document Type: Review

References (63)

1. Shen V, Clarence-Smith K, Hunter C, Jankovic J: Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseases. Tremor Other Hyperkinet Mov (N Y) 2013; 3:pii:tre-03-191-4337-1.
2. Frank S: Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 2010; 6: 657–665.
3. Paleacu D: Tetrabenazine in the treatment of Huntington’s disease. Neuropsychiatr Dis Treat 2007; 3: 545–551.
4. de Tommaso M, Serpino C, Sciruicchio V: Management of Huntington’s disease: role of tetrabenazine. Ther Clin Risk Manag 2011; 7: 123–129.
5. Brandrup E: Reserpinogtetrabenacinved chorea Huntington. Nord Med 1960; 4: 968–969.
6. Dalby MA: Effect of tetrabenazine on extra-pyramidal movement disorders. Br Med J 1969; 2: 422–423.
7. Swash M, Roberts AH, Zakko H, Heathfield KW: Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry 1972; 35: 186–191.
8. Yero T, Rey JA: Tetrabenazine (xenazine), an FDA-approved treatment option for Huntington’s disease-related chorea. P T 2008; 33: 690–694.
9. Lovinger DM: Communication networks in the brain: neurons, receptors, neurotransmitters, and alcohol. Alcohol Res Health 2008; 31: 196–214.
10. Wimalasena K: Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev 2011; 31: 483–519.
11. Fei H, Grygoruk A, Brooks ES, et al: Trafficking of vesicular neurotransmitter transporters. Traffic 2008; 9: 1425–1436.
12. Zheng G, Dwoskin LP, Crooks PA: Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J 2006; 8:E682–E692.
13. Login IS, Cronin MJ, MacLeod RM: Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982; 12: 257–262.
14. Reches A, Burke RE, Kuhn CM, Hassan MN, Jackson VR, Fahn S: Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983; 225: 515–521.
15. Schuldiner S, Liu Y, Edwards RH: Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J Biol Chem 1993; 268: 29–34.
16. Chen JJ, Ondo WG, Dashtipour K, et al: Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 2012; 34: 1487–1504.
17. Roberts MS, McLean S, Millingen KS, Galloway HM: The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986; 29: 703–708.
18. Mehvar R, Jamali F, Watson MW, Skelton D: Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 1987; 15: 250–255.
19. Product Information. Xenazine (Tetrabena-zine). Deerfield, Ovation Pharmaceuticals, Inc., 2008.
20. Product Information. Tetrabenazine Tablets: iNOVA Pharmaceuticals (Aust) Pty Ltd., 1991.
21. Prescribing Xenazine (Tetrabenazine) Tablets: A Healthcare Professional Guide. Approved by FDA as a Part of the Xenazine Risk Evaluation and Mitigation Strategy, 2008.
22. Pidgeon C, Rickards H: The pathophysiology and pharmacological treatment of Huntington disease. Behav Neurol 2013; 26: 245–253.
23. Chitnis S, Karunapuzha CA: Tetrabenazine in Huntington’s disease chorea. Clin Med Ther 2009; 1: 669–681.
24. Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358–362.
25. Food and Drug Administration, Center for Drug Evaluation and Research: Application No. 21-894: Tetrabenazine. Medical Review (Online). www.fda.gov (accessed October 20, 2008).
26. Chatterjee A, Frucht SJ: Tetrabenazine in the treatment of severe pediatric chorea. Mov Disord 2003; 18: 703–706.
27. Poon LH, Kang GA, Lee AJ: Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother 2010; 44: 1080–1089.
28. Fasano A, Bentivoglio AR: Tetrabenazine. Expert Opin Pharmacother 2009; 10: 2883–2896.
29. Sattes H: [The treatment of chorea minor with the monoamine liberator ‘nitoman’] Psychiatr Neurol (Basel) 1960; 140: 13–19.
30. Sattes H, Hase E: Die behandherd extrapyra-midaler hypokinesien unto besonderer beri-icksichtigung der chorea Huntington. Psychiatr Neurol Neurochirurg (Aust) 1964; 67: 289.
31. Huntington Study Group: Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006; 66: 366–372.
32. Kenney C, Hunter C, Davidson A, et al: Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord 2007; 22: 10–13.
33. Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J: A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008; 31: 127–133.
34. Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, Bentivoglio AR: The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008; 31: 313–318.
35. Tardive dyskinesia: summary of a task force report of the American psychiatric association. By the task force on late neurological effects of antipsychotic drugs. Am J Psychiatry 1980; 137: 1163–1172.
36. Waln O, Jankovic J: An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013; 3:pii:tre-03-161-4138-1.
37. Cloud LJ, Zutshi D, Factor SA: Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 2014; 11: 166–176.
38. Aquino CC, Lang AE: Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord 2014; 20(suppl 1):S113–S117.
39. Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Münchau A: Pharmacological treat ment of tic disorders and Tourette syndrome. Neuropharmacology 2013; 68: 143–149.
40. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. American Psychiatric Association, 2013.
41. Gilbert DL, Jankovic J: Pharmacological treatment of Tourette syndrome. J Obsessive Compuls Relat Disord 2014; 3: 407–414.
42. Mogwitz S, Buse J, Ehrlich S, Roessner V: Clinical pharmacology of dopamine-modulating agents in Tourette’s syndrome. Int Rev Neurobiol 2013; 112: 281–349.
43. Hartmann A: Clinical pharmacology of non-dopaminergic drugs in Tourette syndrome. Int Rev Neurobiol 2013; 112: 351–372.
44. Shaw ZA, Coffey BJ: Tics and Tourette syndrome. Psychiatr Clin North Am 2014; 37: 269–286.
45. Jinnah HA, Hess EJ: Experimental therapeutics for dystonia. Neurotherapeutics 2008; 5: 198–209.
46. Silverdale MA: Other movement disorders. Medicine 2012; 40: 536–539.
47. Kartha N: Dystonia. Clin Geriatr Med 2006; 22: 899–914, vii.
48. Jankovic J: Treatment of dystonia. Lancet Neurol 2006; 5: 864–872.
49. Kartha N: Therapeutic challenges in dystonia. Neurol Clin 2010; 28: 927–940.
50. Godwin-Austen RB, Clark T: Persistent phe-nothiazine dyskinesia treated with tetrabenazine. Br Med J 1971; 4: 25–26.
51. Kazamatsuri H, Chien C, Cole JO: Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972; 27: 95–99.
52. Asher SW, Aminoff MJ: Tetrabenazine and movement disorders. Neurology 1981; 31: 1051–1054.
53. Jankovic J: Treatment of hyperkinetic movement disorders with tetrabenazine: a double- blind crossover study. Ann Neurol 1982; 11: 41–47.
54. Watson MW, Skelton D, Jamali F: Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can J Psychiatry 1988; 33: 11–13.
55. Ondo WG, Hanna PA, Jankovic J: Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999; 156: 1279–1281.
56. Paleacu D, Giladi N, Moore O, et al: Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004; 27: 230–233.
57. Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22: 193–197.
58. Sweet RD, Bruun R, Shapiro E, et al: Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Arch Gen Psychiatry 1974; 31: 857–861.
59. Jankovic J, Glaze DG, Frost JD Jr: Effect of tetrabenazine on tics and sleep of Gilles de la Tourette’s syndrome. Neurology 1984; 34: 688–692.
60. Jankovic J, Rohaidy H: Motor, behavioral and pharmacologic findings in Tourette’s syndrome. Can J Neurol Sci 1987; 14(3 suppl):541–546.
61. Jankovic J, Orman J: Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988; 38: 391–394.
62. Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D: Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 2008; 28: 443–459.
63. Marsden CD, Marion MH, Quinn N: The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984; 47: 1166–1173.